Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased to announce that Dr. Carlos Robles-Medranda, and his dedicated team at the Instituto Ecuatoriano de Enfermedades Digestivas y Pélvicas (IECED) located within OMNI Hospital in Guayaquil, Ecuador, achieved a significant milestone. Over the past 18 months, this skilled medical team has successfully performed more than 700 advanced endoscopic procedures utilizing the Cellvizio® platform, demonstrating the value of this technology in supporting accelerated detection and diagnosis, and guiding informed treatment for patient care using high-quality, real-time, in vivo cellular imaging.
The IECED-OMNI Hospital (https://ieced.com.ec), internationally renowned for its expertise in digestive and pelvic disease management, is a key player of Ecuador’s Endoscopy Network-a comprehensive healthcare network operating over 10 top-tier facilities nationwide and a world-renowned training center for interventional endoscopists, endorsed by the World Endoscopy Organization (WEO). Under the leadership of Dr. Robles-Medranda, a respected expert in therapeutic endoscopy, the IECED team has adopted and integrated the Cellvizio® platform into routine clinical practice in the field of gastroenterology, allowing for improved diagnostic accuracy and more targeted therapeutic interventions.
“Confocal Laser Endomicroscopy is a key adjunct to our endoscopy armamentarium at IECED, addressing a variety of indications in gastroenterology“, declared Dr. Carlos Robles-Medranda, Director General of IECED. “For pancreatic cyst and biliary stricture characterization, early gastric cancer detection or identification of previously undetectable food intolerances, endomicroscopy plays a vital role for our physicians and patients. I have been a user and developer of endomicroscopic applications for more than a decade and could not be more thrilled to see how this technology has taken a key role in these indications. We continuously explore new ways to use this unique technology in combination with other platforms and AI.”
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies added: “We are very proud to see renowned experts like Dr. Robles-Medranda adopt and utilize our platform so extensively across diverse clinical applications, underscoring the unique value of Cellvizio in the daily practice of many physicians and its capability to handle high volumes. I am very excited to see this adoption expand further, in particular in South America where IECED plays a key role.”
